Precision Drilling Corporation (PDS)
NYSE: PDS · Real-Time Price · USD
53.58
-0.60 (-1.11%)
Aug 4, 2025, 4:00 PM - Market closed
ShockWave Medical Stock Forecast
Stock Price Forecast
The 2 analysts that cover ShockWave Medical stock have a consensus rating of "Buy" and an average price target of $86, which forecasts a 60.51% increase in the stock price over the next year. The lowest target is $72 and the highest is $100.
Price Target: $86.00 (+60.51%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ShockWave Medical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $89 → $100 | Buy | Maintains | $89 → $100 | +86.64% | Jul 31, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $72 | Buy | Initiates | $72 | +34.38% | Jul 15, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $101 → $95 | Buy | Maintains | $101 → $95 | +77.30% | Jul 15, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $81 → $101 | Buy | Maintains | $81 → $101 | +88.50% | May 6, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $100 → $81 | Buy | Maintains | $100 → $81 | +51.18% | Feb 20, 2024 |
Financial Forecast
Revenue This Year
1.92B
from 1.90B
Increased by 0.98%
Revenue Next Year
1.95B
from 1.92B
Increased by 1.30%
EPS This Year
8.05
from 7.81
Increased by 3.11%
EPS Next Year
9.47
from 8.05
Increased by 17.62%
Financial currency is CAD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.1B | 2.1B | 2.0B | ||
| Avg | 1.9B | 1.9B | 2.0B | ||
| Low | 1.8B | 1.7B | 1.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.0% | 11.5% | 4.2% | ||
| Avg | 1.0% | 1.3% | 0.9% | ||
| Low | -7.8% | -12.5% | -4.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.73 | 12.46 | 15.73 | ||
| Avg | 8.05 | 9.47 | 13.80 | ||
| Low | 6.33 | 6.11 | 11.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 37.4% | 54.7% | 66.0% | ||
| Avg | 3.1% | 17.6% | 45.6% | ||
| Low | -19.0% | -24.2% | 22.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.